Optimal treatment of Imipenem and meropenem against bloodstream infections caused by the Citrobacter spp.

IF 3.4 3区医学 Q2 INFECTIOUS DISEASES

BMC Infectious Diseases Pub Date : 2025-03-17 DOI:10.1186/s12879-025-10760-6

Lushun Jiang, Jiaheng Fang, Jiajie Zhang, Kanghui Zhang, Junpeng Yue, Kaixuan Dong, Jiaying Shen, Yunqing Qiu, Wei Yu

{"title":"Optimal treatment of Imipenem and meropenem against bloodstream infections caused by the Citrobacter spp.","authors":"Lushun Jiang, Jiaheng Fang, Jiajie Zhang, Kanghui Zhang, Junpeng Yue, Kaixuan Dong, Jiaying Shen, Yunqing Qiu, Wei Yu","doi":"10.1186/s12879-025-10760-6","DOIUrl":null,"url":null,"abstract":"Objectives: This work was to investigate the optimal treatments of imipenem (IPM) and meropenem (MEM) against bloodstream infections (BSIs) caused by Citrobacter spp.Methods: A total of 230 nonduplicate BSIs Citrobacter spp. were collected from 2014 to 2020 in three hospitals in Zhejiang Province in China. The minimum inhibitory concentrations (MICs) of 17 antibiotics were determined. Monte Carlo simulation (MCS) was used to investigate the cumulative fraction of response (CFR) of 8 regimens of IPM and 10 regimens of MEM.Results: C. freundii (Cfr) was the predominant epidemic isolate (83.9%, 193/230). The resistance rates to IPM and MEM showed an increasing trend from 2015 to 2019. Fosfomycin showed excellent activity from 2014 to 2020. The probability of target attainment of IPM and MEM by prolonged 3 h infusion therapy (PIT) was higher than that by traditional 0.5 h (h) infusion therapy (TIT) during the same administration dosage. The CFR of all IPM regimes was above 90%, while MEM with 500 mg q8h was lower than 90%, especially for Cfr.Conclusions: Cfr is the most common BSIs. Citrobacter spp. PIT is more adequate to provide activity against BSIs Citrobacter spp., especially for IPM.","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"366"},"PeriodicalIF":3.4000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912752/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12879-025-10760-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This work was to investigate the optimal treatments of imipenem (IPM) and meropenem (MEM) against bloodstream infections (BSIs) caused by Citrobacter spp.

Methods: A total of 230 nonduplicate BSIs Citrobacter spp. were collected from 2014 to 2020 in three hospitals in Zhejiang Province in China. The minimum inhibitory concentrations (MICs) of 17 antibiotics were determined. Monte Carlo simulation (MCS) was used to investigate the cumulative fraction of response (CFR) of 8 regimens of IPM and 10 regimens of MEM.

Results: C. freundii (Cfr) was the predominant epidemic isolate (83.9%, 193/230). The resistance rates to IPM and MEM showed an increasing trend from 2015 to 2019. Fosfomycin showed excellent activity from 2014 to 2020. The probability of target attainment of IPM and MEM by prolonged 3 h infusion therapy (PIT) was higher than that by traditional 0.5 h (h) infusion therapy (TIT) during the same administration dosage. The CFR of all IPM regimes was above 90%, while MEM with 500 mg q8h was lower than 90%, especially for Cfr.

Conclusions: Cfr is the most common BSIs. Citrobacter spp. PIT is more adequate to provide activity against BSIs Citrobacter spp., especially for IPM.

查看原文本刊更多论文

使用亚胺培南和美罗培南治疗由柠檬酸杆菌属引起的血液感染的最佳方法

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Infectious Diseases 医学-传染病学

CiteScore

6.50

自引率

0.00%

发文量

860

审稿时长

3.3 months

期刊介绍： BMC Infectious Diseases is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of infectious and sexually transmitted diseases in humans, as well as related molecular genetics, pathophysiology, and epidemiology.